Background: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. Objective: We investigated the effect of dimethyl fumarate on absolute lymphocyte counts and CD4+/CD8+ T cells in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in routine practice. Methods: Lymphocyte data were collected via medical chart abstraction. Primary endpoint: change from baseline in absolute lymphocyte count and CD4+/CD8+ counts at 6-month intervals following dimethyl fumarate initiation. Results: Charts of 483 patients were abstracted and 476 patients included i...
Objective: To assess functional changes in lymphocyte repertoire and subsequent clinical implication...
Early lymphopenia is a known side effect of dimethyl fumarate, a disease-modifying therapy for MS. H...
Background: Dimethyl fumarate (DMF) is licensed for treatment of relapsing–remitting multiple sclero...
Background: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically ...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fuma...
Background: Dimethyl fumarate (DMF) is a disease-modifying drug for relapsing-remitting multiple scl...
Background: Dimethyl fumarate (DMF) alters the phenotype of circulating immune cells and causes lymp...
BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with re...
Objective: To assess functional changes in lymphocyte repertoire and subsequent clinical implication...
Background: delayed-release dimethyl fumarate (DMF) is a disease modifying therapy for relapsing–rem...
BACKGROUND Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with ...
Objective: To assess functional changes in lymphocyte repertoire and subsequent clinical implication...
Early lymphopenia is a known side effect of dimethyl fumarate, a disease-modifying therapy for MS. H...
Background: Dimethyl fumarate (DMF) is licensed for treatment of relapsing–remitting multiple sclero...
Background: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically ...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl fuma...
Background: Dimethyl fumarate (DMF) is a disease-modifying drug for relapsing-remitting multiple scl...
Background: Dimethyl fumarate (DMF) alters the phenotype of circulating immune cells and causes lymp...
BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with re...
Objective: To assess functional changes in lymphocyte repertoire and subsequent clinical implication...
Background: delayed-release dimethyl fumarate (DMF) is a disease modifying therapy for relapsing–rem...
BACKGROUND Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with ...
Objective: To assess functional changes in lymphocyte repertoire and subsequent clinical implication...
Early lymphopenia is a known side effect of dimethyl fumarate, a disease-modifying therapy for MS. H...
Background: Dimethyl fumarate (DMF) is licensed for treatment of relapsing–remitting multiple sclero...